September 30, 2022
3 min watch
Save
VIDEO: ViaLase shares safety, efficacy updates for glaucoma femtosecond laser
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Shawn O’Neil of ViaLase discusses the company’s noninvasive OCT-driven femtosecond laser for glaucoma treatment.
In a case series of 18 eyes that underwent a procedure using ViaLase’s femtosecond laser, 100% of patients experienced a greater than 20% IOP reduction at 24 months, with a 31% mean IOP reduction rate among the total cohort.
Published by:
Sources/Disclosures
Collapse
Source:
O'Neil S. ViaLase. Presented at: Eyecelerator@AAO; Sept. 29, 2022; Chicago.
Disclosures:
O’Neil reports being the chief commercial officer of ViaLase.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.